WINTON GROUP Ltd Invests $6.41 Million in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

WINTON GROUP Ltd purchased a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 15,500 shares of the company's stock, valued at approximately $6,408,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Flossbach Von Storch SE boosted its position in shares of IDEXX Laboratories by 5,439.3% during the fourth quarter. Flossbach Von Storch SE now owns 473,336 shares of the company's stock worth $195,696,000 after buying an additional 464,791 shares during the period. William Blair Investment Management LLC raised its stake in IDEXX Laboratories by 701.6% during the 4th quarter. William Blair Investment Management LLC now owns 422,133 shares of the company's stock valued at $174,527,000 after acquiring an additional 369,471 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in IDEXX Laboratories by 265.6% during the 4th quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company's stock worth $179,867,000 after acquiring an additional 316,048 shares during the period. Seilern Investment Management Ltd bought a new position in shares of IDEXX Laboratories in the fourth quarter worth $113,104,000. Finally, Vontobel Holding Ltd. grew its stake in shares of IDEXX Laboratories by 90.1% in the fourth quarter. Vontobel Holding Ltd. now owns 418,563 shares of the company's stock worth $173,051,000 after purchasing an additional 198,404 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.

Remove Ads

IDEXX Laboratories Trading Down 0.0 %

IDXX traded down $0.10 during trading on Monday, reaching $415.77. The company had a trading volume of 186,051 shares, compared to its average volume of 580,374. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $548.88. The firm's 50-day simple moving average is $437.07 and its 200 day simple moving average is $442.57. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. The company has a market cap of $33.70 billion, a price-to-earnings ratio of 38.94, a PEG ratio of 3.41 and a beta of 1.39.

Analyst Ratings Changes

IDXX has been the subject of a number of recent analyst reports. Piper Sandler increased their target price on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research report on Monday, February 10th. Morgan Stanley dropped their target price on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a report on Wednesday, January 29th. StockNews.com lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Tuesday, March 25th. Leerink Partners initiated coverage on IDEXX Laboratories in a research note on Monday, December 2nd. They issued an "outperform" rating and a $500.00 price objective on the stock. Finally, Barclays raised their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research note on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $533.75.

Insider Buying and Selling

In other news, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the transaction, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director M Anne Szostak sold 3,000 shares of the company's stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares in the company, valued at $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 2.11% of the company's stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.